Johnson & Johnson gained Inlexzo, formerly known as TAR-200, when it acquired privately held Taris Biomedical in 2019. The deal gave J&J a treatment it says could change way the “non-muscle invasive” ...
A new database targeting chronic urinary tract infections (UTIs)—a long-overlooked condition that may begin in childhood—is set to help researchers uncover why millions of women and girls worldwide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback